Targeted protein degradation (TPD) is reshaping leukemia research by offering a novel approach to breaking down BRD4, a key driver in Acute Lymphoblastic Leukemia (ALL). BRD4, a member of the BET protein family, plays a crucial role in gene regulation and disease progression, making it a significant therapeutic target. While traditional small- molecule inhibitors have been widely used, they often struggle with incomplete inhibition and the development of resistance. TPD offers a novel approach by leveraging the cell’s natural degradation pathways to selectively eliminate BRD4, providing a more effective and durable therapeutic strategy.

Key highlights include:

• A case study on BRD4 degradation in leukemia models
• Comparative analysis of treatment responses
• Best practices for optimizing HTRF™ assays

Discover how HTRF based immunoassays empower preclinical leukemia research and accelerate drug discovery.

For research use only. Not for use in diagnostic procedures